APS 2011 Chronic Non-Cancer Pain

Initial analysis of the effects of duloxetine vs. placebo in patients with chronic low back pain indicates duloxetine has both brain and behavioral effects in this population, Kevin A. Johnson, of Stanford University School of Medicine, Palo Alto, CA, and colleagues reported during the American Pain Society’s 30th Annual Scientific Meeting.

Methylnaltrexone bromide, a selective peripherally acting mu-opioid receptor antagonist, is effective for the long-term treatment of opioid-induced constipation resulting from chronic opioid therapy in chronic non-cancer pain, as demonstrated by study data presented at the American Pain Society’s 30th Annual Scientific Meeting.

At the American Pain Society’s 30th Annual Scientific Meeting, study data presented demonstrated that low-dose intrathecal morphine improves both Numeric Pain Rating Scale (NPS) scores and Multidimensional Pain Inventory (MPI) scores in patients with chronic non-cancer pain.

Patients with chronic low back pain treated with REC1100, a sublingual formulation of dexmedetomidine, showed a significant decrease in mean Visual Analog Scale of Pain (VASPain) scores two hours after dosing compared with those receiving placebo, investigators reported during the American Pain Society’s 30th Annual Scientific Meeting.

Investigators reporting at the American Pain Society’s 30th Annual Scientific Meeting shared results of their study regarding musculoskeletal pain in sufferers of post-traumatic stress disorder (PTSD).

Results of a post-hoc analysis presented at the American Pain Society’s 30th Annual Scientific Meeting demonstrated that tapentadol extended-release is associated with comparable analgesia and better gastrointestinal tolerability than oxycodone HCl controlled-release.

Maximizing acute pain relief while minimizing the incidence of adverse events prevents the evolution of acute postoperative pain into chronic pain.

In a study presented at the American Pain Society’s 30th Annual Scientific Meeting, fentanyl buccal tablet was shown to be more effective than traditional short-acting opioids for the management of breakthrough pain in opioid-tolerant patients.

In a trial designed to evaluate the analgesic effects of fulranumab in patients with chronic low back pain (cLBP), the agent did not demonstrate efficacy vs. placebo but was generally well tolerated, as reported by the study authors at the American Pain Society’s 30th Annual Scientific Meeting.

Researchers at the American Pain Society’s 30th Annual Scientific Meeting discussed data from a review of spontaneous adverse events reported with Embeda (morphine sulfate and naltrexone HCl) treatment, with a focus on events potentially related to product tampering.